SMT202000521T1 - Combinazione tripla di antagonisti puri del recettore 5-ht6, di inibitori della acetilcolinesterasi e di un antagonista del recettore nmda - Google Patents

Combinazione tripla di antagonisti puri del recettore 5-ht6, di inibitori della acetilcolinesterasi e di un antagonista del recettore nmda

Info

Publication number
SMT202000521T1
SMT202000521T1 SM20200521T SMT202000521T SMT202000521T1 SM T202000521 T1 SMT202000521 T1 SM T202000521T1 SM 20200521 T SM20200521 T SM 20200521T SM T202000521 T SMT202000521 T SM T202000521T SM T202000521 T1 SMT202000521 T1 SM T202000521T1
Authority
SM
San Marino
Prior art keywords
pure
acetylcholinesterase inhibitors
triple combination
receptor antagonist
receptor antagonists
Prior art date
Application number
SM20200521T
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Ramasastri Kambhampati
Pradeep Jayarajan
Venkateswarlu Jasti
Gopinadh Bhyrapuneni
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of SMT202000521T1 publication Critical patent/SMT202000521T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20200521T 2016-05-18 2016-08-03 Combinazione tripla di antagonisti puri del recettore 5-ht6, di inibitori della acetilcolinesterasi e di un antagonista del recettore nmda SMT202000521T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641017204 2016-05-18
EP16763575.4A EP3458039B1 (en) 2016-05-18 2016-08-03 Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
PCT/IB2016/054672 WO2017199070A1 (en) 2016-05-18 2016-08-03 Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist

Publications (1)

Publication Number Publication Date
SMT202000521T1 true SMT202000521T1 (it) 2020-11-10

Family

ID=56896730

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200521T SMT202000521T1 (it) 2016-05-18 2016-08-03 Combinazione tripla di antagonisti puri del recettore 5-ht6, di inibitori della acetilcolinesterasi e di un antagonista del recettore nmda

Country Status (29)

Country Link
US (1) US11253514B2 (it)
EP (1) EP3458039B1 (it)
JP (1) JP6629464B2 (it)
KR (1) KR102016120B1 (it)
CN (1) CN109152751A (it)
AU (1) AU2016407426B2 (it)
BR (1) BR112018073410A2 (it)
CA (1) CA3023836C (it)
CY (1) CY1123644T1 (it)
DK (1) DK3458039T3 (it)
EA (1) EA038087B1 (it)
ES (1) ES2815555T3 (it)
HK (1) HK1258022A1 (it)
HR (1) HRP20201412T1 (it)
HU (1) HUE052077T2 (it)
IL (1) IL262920B (it)
LT (1) LT3458039T (it)
MA (1) MA45002B1 (it)
MD (1) MD3458039T2 (it)
MX (1) MX384146B (it)
NZ (1) NZ747797A (it)
PL (1) PL3458039T3 (it)
PT (1) PT3458039T (it)
RS (1) RS60849B1 (it)
SG (1) SG11201809726UA (it)
SI (1) SI3458039T1 (it)
SM (1) SMT202000521T1 (it)
WO (1) WO2017199070A1 (it)
ZA (1) ZA201807310B (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ761037A (en) * 2017-07-03 2022-10-28 Suven Life Sciences Ltd New uses of a pure 5-ht6 receptor antagonist
HRP20250882T1 (hr) * 2019-12-02 2025-09-26 Suven Life Sciences Limited Kombinacije masupirdina sa donepezilom ili memantinom za liječenje bihevioralnih i psiholoških simptoma kod pacijenata sa demencijom
BR112022010493A2 (pt) 2019-12-02 2022-09-06 Suven Life Sciences Ltd Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência
CN117024326B (zh) * 2023-07-26 2026-06-05 平顶山学院 5位氨基取代吲哚化合物及其制备方法和在抗乙酰胆碱酯酶药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509232B1 (en) * 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
ATE401307T1 (de) * 2002-11-28 2008-08-15 Suven Life Sciences Ltd N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
CA2929309C (en) 2013-12-02 2018-07-03 Suven Life Sciences Limited Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
EP3134392B1 (en) 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof

Also Published As

Publication number Publication date
HUE052077T2 (hu) 2021-04-28
ZA201807310B (en) 2020-01-29
HK1258022A1 (zh) 2019-11-01
MA45002A (fr) 2019-03-27
EP3458039B1 (en) 2020-07-15
PL3458039T3 (pl) 2020-12-28
CA3023836A1 (en) 2017-11-23
KR102016120B1 (ko) 2019-10-21
LT3458039T (lt) 2020-11-25
NZ747797A (en) 2020-07-31
EA201892528A1 (ru) 2019-04-30
ES2815555T3 (es) 2021-03-30
IL262920A (en) 2018-12-31
MD3458039T2 (ro) 2020-10-31
CN109152751A (zh) 2019-01-04
AU2016407426B2 (en) 2019-11-28
CY1123644T1 (el) 2022-03-24
EA038087B1 (ru) 2021-07-05
MX2018014184A (es) 2019-02-25
DK3458039T3 (da) 2020-09-14
SI3458039T1 (sl) 2020-11-30
RS60849B1 (sr) 2020-10-30
EP3458039A1 (en) 2019-03-27
SG11201809726UA (en) 2018-12-28
HRP20201412T1 (hr) 2021-02-05
CA3023836C (en) 2019-08-27
MA45002B1 (fr) 2020-10-28
US11253514B2 (en) 2022-02-22
MX384146B (es) 2025-03-14
PT3458039T (pt) 2020-09-14
WO2017199070A1 (en) 2017-11-23
IL262920B (en) 2020-05-31
US20190160055A1 (en) 2019-05-30
AU2016407426A1 (en) 2018-11-22
KR20190002697A (ko) 2019-01-08
JP6629464B2 (ja) 2020-01-15
BR112018073410A2 (pt) 2019-03-19
JP2019516698A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
SG11201700943TA (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
ZA202104313B (en) Vasopressin receptor antagonists and products and methods related thereto
IL262920B (en) Triple combination of pure 5-HT6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonist
PL3495352T3 (pl) Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie
ZA201805496B (en) Somatostatin receptor antagonist compounds and methods of using the same
IL262921B (en) Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors
IL271694A (en) Novel uses of a pure 6HT–5 receptor antagonist
ZA201807311B (en) Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
IL264405B (en) Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
IL254593A0 (en) Combination dosage form of mu opioid receptor antagonist and opioid agent
EP3277665A4 (en) Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof
EP3388423A4 (en) ANTAGONIST OF THE RECEIVER NK1